Arm 1 for Tuberous Sclerosis

"This clinical study seeks 45 participants with adenoma sebaceum aged between 2 and 21. It is essential that applicants have 3 or more facial angiofibromas of grade ≥2 colour for each lesion, agree to abstain from intercourse or use an accepted form of birth control if their partner does not get a vasectomy, be in good health based on medical history/physical exam results, and are willing/able to comply with trial requirements."

"Presently, Arm 1 has 125 ongoing studies with 13 of them in the third phase. Of these trials some are occurring within Cincinnati, Ohio while 1074 sites across the globe host clinical trials for this arm."

"We rate Arm 1's safety at 2, as Phase 2 trials have generated some data affirming security without the same level of evidence for efficacy."

"The prerequisite number of eligible participants needed to commence the trial is 45. Aucta Pharmaceuticals, Inc will be managing recruitment and administration from multiple sites including Children's Hospital of Los Angeles' Division of Neurology in LA and Boston Children's Hospital in Massachusetts."

"Rejection of a transplanted liver is typically handled with Arm 1, which is also suitable for treating disease, kidney issues and renal angiomyolipomas."

"Per the rules of this medical experiment, participants must be no older than 21 years old and at least 2 years old."

"According to clinicaltrials.gov, this research is currently recruiting participants with the initial posting date being April 12th 2017 and modifications made on February 2nd 2022."